Opus Genetics Enters Material Definitive Agreement
Ticker: IRD · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1228627
Sentiment: neutral
Topics: material-definitive-agreement, corporate-actions
TL;DR
Opus Genetics just signed a big deal, filing an 8-K on 6/13/25.
AI Summary
On June 13, 2025, Opus Genetics, Inc. entered into a material definitive agreement. The company, formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Durham, NC.
Why It Matters
This filing indicates a significant development in Opus Genetics' business operations, potentially impacting its strategic direction and future performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- Ocuphire Pharma, Inc. (company) — Former company name
- Rexahn Pharmaceuticals, Inc. (company) — Former company name
- June 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Durham, NC (location) — Address of principal executive offices
FAQ
What type of material definitive agreement did Opus Genetics, Inc. enter into?
The filing states that Opus Genetics, Inc. entered into a material definitive agreement on June 13, 2025, but the specific details of the agreement are not provided in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 13, 2025.
What are the former names of Opus Genetics, Inc. mentioned in the filing?
Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.
In which state is Opus Genetics, Inc. incorporated?
Opus Genetics, Inc. is incorporated in Delaware.
What is the principal executive office address for Opus Genetics, Inc.?
The principal executive office address for Opus Genetics, Inc. is 8 Davis Drive, Durham, NC 27713.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Opus Genetics, Inc. (IRD).